Call Now
We have developed a proprietary AI platform that converges bioinformatics, machine learning, deep learning and structural biology tools for automated biomolecule (drug) discovery
We offer services through our AI platform to clients who need evaluation of their biological data and target molecules pre- and during development, leading to clinical studies
Three (3) cancer therapeutic peptides and two (2) therapeutic enzymes discovered from our proprietary biological datasets (as demonstrations)
Our key customers include pharmaceutical & biotech companies, contract research organizations, research centers, investors, academic and government institutes
We provide AI-backed services that enable robust identification and characterization of known and unknown biomolecules of healthcare importance
We algorithmically converge four (4) fields – bioinformatics, machine learning, deep learning and structural biology – to bypass extensive wet-lab processes in screening biomolecules of interest from various biological datasets
At a comfortable cost to our clients, our AI platform has configurations that can enable the engineering of biomolecules to meet specified requirements for different clinical outcomes
Although we have proprietary biodata, we offer bioanalytic services tailored to client requirements, including evaluating novel models in alignment with specific disease targets
Our services offer an advanced suite of tools that provide accurate predictions and actionable insights, increasing the likelihood of success before wet lab experiments or other processes.
© Avrobiomics. All Rights Reserved.